<i>TP53</i> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer - Concepedia

Concepedia

Publication | Open Access

<i>TP53</i> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer

DOI Full Paper Access

161

Citations

29

References

2018

Year

Bram De Laere, Steffi Oeyen, Markus Mayrhofer, Tom Whitington, Pieter‐Jan van Dam, Peter Van Oyen, Christophe Ghysel, J Ampe, Piet Ost, Wim Demey,

Clinical Cancer Research

Abstract

In an all-comer cohort, tumor burden estimates and <i>TP53</i> outperform any <i>AR</i> perturbation to infer prognosis.See related commentary by Rebello et al., p. 1699.

References

	Year	Citations

Page 1